VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Howard S. Hochster on TAS-102 Compared to 5FU

Howard S. Hochster, MD
Published: Saturday, Jul 04, 2015



Howard S. Hochster, MD, professor of Medicine and Associate Director for Clinical Sciences, Yale Cancer Center, discusses the potential of TAS-102 for colorectal cancer.

TAS-102 was evaluated in the RECOURSE study, which included 800 patients with metastatic colorectal cancer who were refractory or intolerant to standard therapies.

The drug has a very short half life, around 6 hours, and be given twice a day. It is a different kind of antimetabolite than 5-fluorouracil (5-FU) and is active in 5FU- resistant cells pre-clinically, says Hochster. The drug has a lot of potential to be combined with other agents, including targeted therapies. It may the basis for a lot of chemotherapy programs across multiple tumor types and will serve as a good alternative to 5FU, says Hochster.




Howard S. Hochster, MD, professor of Medicine and Associate Director for Clinical Sciences, Yale Cancer Center, discusses the potential of TAS-102 for colorectal cancer.

TAS-102 was evaluated in the RECOURSE study, which included 800 patients with metastatic colorectal cancer who were refractory or intolerant to standard therapies.

The drug has a very short half life, around 6 hours, and be given twice a day. It is a different kind of antimetabolite than 5-fluorouracil (5-FU) and is active in 5FU- resistant cells pre-clinically, says Hochster. The drug has a lot of potential to be combined with other agents, including targeted therapies. It may the basis for a lot of chemotherapy programs across multiple tumor types and will serve as a good alternative to 5FU, says Hochster.





View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x